Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Recent developments of agents targeting Vibrio cholerae : patents and literature data50
The role of patent analysis in target selection43
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)41
Malaria transmission blocking compounds: a patent review40
Update on mGlu4 modulator patents: 2017 to present37
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)35
FAK inhibitors in cancer, a patent review – an update on progress34
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities31
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)30
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)29
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review28
Caspase inhibitors: a review on recently patented compounds (2016–2023)28
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)27
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present26
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)26
A patent review of MAPK inhibitors (2018 – present)25
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)24
An updated patent review of AKT inhibitors (2020 – present)23
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201322
Proteolysis-Targeting Chimeras (PROTACs) targeting the BCR-ABL for the treatment of chronic myeloid leukemia – a patent review22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
Antiprotozoal drugs: challenges and opportunities21
Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)21
Targeting the LPA1 signaling pathway for fibrosis therapy: a patent review (2010-present)20
GPR120 agonists for the treatment of type 2 diabetes: an updated patent review (2020-present)20
Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 202319
PDE1 inhibitors: a review of the recent patent literature (2008-present)17
Small-molecule RNA ligands: a patent review (2018–2024)17
Inhibition of GTPase KRAS G12D : a review of patent literature17
Recent advances in the development of P2Y 14 R inhibitors: a patent and literature review (2018-present)17
Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)16
Therapeutic compounds targeting interleukin-1 receptor-associated kinase 4 (IRAK4): an updated patent review (2019 to present)16
A patent review of P2X7 receptor antagonists to treat inflammatory diseases (2018–present)16
A patent review of IDH1 inhibitors (2018-present)16
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)16
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders16
The challenging inhibition of Aldose Reductase for the treatment of diabetic complications: a 2019–2023 update of the patent literature16
Dopamine D3 receptor ligands: a patent review (2014–2020)15
Antimalarial drugs: what’s new in the patents?15
An updated patent review on PD-1/PD-L1 antagonists (2022-present)15
A patent and literature review of CDK12 inhibitors15
An updated patent review of MALT1 inhibitors (2021–present)15
Part-II: an update of Schiff bases synthesis and applications in medicinal chemistry-a patent review (2016-2023)14
Biofilm and bacterial membrane vesicles: recent advances13
Trends in covalent drug discovery: a 2020–23 patent landscape analysis focused on select covalent reacting groups (CRGs) found in FDA-approved drugs13
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)13
A patent review of NLRP3 inhibitors to treat autoimmune diseases13
Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020–2024)13
Sirtuin modulators: a review of patents from 2020 to 202413
The management ofBabesia, amoeba and other zoonotic diseases provoked by protozoa12
Biomedical applications of prokaryotic carbonic anhydrases: an update12
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) in cancer: a patent review12
Progress with polo-like kinase (PLK) inhibitors: a patent review (2018–present)12
A patent review of von Hippel-Lindau (VHL)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019–present)12
Are patents important indicators of innovation for Chagas disease treatment?12
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents12
An updated patent review of EZH2 inhibitors (2024–present)12
An updated patent review of TRPA1 antagonists (2020 – present)11
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 1-patent granted11
Implementation and outcomes of China’s drug patent linkage system: lessons from international experience11
An updated patent review of GPR40/ FFAR1 modulators (2020 – present)11
The patent review of the biological activity of tropane containing compounds11
Correction11
Challenges, opportunities, and therapeutic potential of JAK inhibitors and their derived PROTACs (2022 – 2023)10
A patent review of BRD4 inhibitors (2020–present)10
Protein tyrosine phosphatase inhibitors: a patent review and update (2012–2023)10
Histamine H 3 receptor antagonists/inverse agonists: a patent review (October 2017 – December 2023) documenting progress10
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)10
A patent review of histone deacetylase 8 (HDAC8) inhibitors (2013–present)10
An insight into the last 5-year patents on Porphyromonas gingivalis and Streptococcus mutans , the pivotal pathogens in the oral cavity10
Small molecule ATM inhibitors as potential cancer therapy: a patent review (2003–present)10
A patent review of peptidylarginine deiminase 4 (PAD4) inhibitors (2014–present)9
An updated patent review of small molecule KCNT1 inhibitors (2022–2024)9
Quorum sensing inhibitors (QSIs): a patent review (2019–2023)9
A patent review of CXCR7 modulators (2019-present)9
Rho kinase inhibitors: a patent review (2017–2023)9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)9
Patent landscape of small molecule inhibitors of METTL3 (2020-present)9
A patent review of selective CDK9 inhibitors in treating cancer9
Impact of patent-granting differences between Japan and the United States on patent protection for medical methods: insights from genome editing patents9
Bruton’s tyrosine kinase (BTK) inhibitors: an updated patent review (2019–2024)9
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 – present): part 2 - patent published9
Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections – structure proposal for Phaeno Therapeutics drug candid8
Recent advances in the development of STING inhibitors: an updated patent review8
Nurr1 modulators – a patent review (2019–present)8
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)8
A patent perspective of antiangiogenic agents8
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present)8
Recent advances on patents of Plasmodium falciparum dihydroorotate dehydrogenase ( Pf DHODH) inhibitors as antimalarial agents8
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)8
Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 20238
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update8
A patent review on arachidonic acid lipoxygenase (LOX) inhibitors for the treatment of neurodegenerative diseases (2018-present)8
Therapeutic cysteine protease inhibitors: a patent review (2018–present)8
Selective COX-2 inhibitors as anticancer agents: a patent review (2018-2023)8
An updated patent review on monoamine oxidase (MAO) inhibitors8
A patent review of xanthine oxidase inhibitors (2021–present)7
An updated patent review of Mcl-1 inhibitors (2020–2022)7
Proteasome inhibitors as anticancer agents7
N-acetylgalactosamine delivery systems for RNA therapeutics: a patent perspective7
Pitfalls in patenting academic CAR-T cells therapy7
An updated patent review of stimulator of interferon genes agonists (2021 – present)7
Anticancer drugs: where are we now?7
A patent review of pharmaceutical and therapeutic applications of oxadiazole derivatives for the treatment of chronic diseases (2013–2021)7
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)7
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)7
Conjugates of monocyclic β-lactams and siderophore mimetics: a patent evaluation (WO2023023393)7
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)6
An updated patent review of BRD4 degraders6
The therapeutic potential of phosphodiesterase 9 (PDE9) inhibitors: a patent review (2018-present)6
A review of the patent literature surrounding TRPV1 modulators6
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present6
An updated patent review of glutaminase inhibitors (2019–2022)6
A patent review of anti-coronavirus agents targeting the spike-ACE2 interaction (2019–present)6
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021–2024)5
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)5
Mycobacterium tuberculosis inhibitors: an updated patent review (2021–present)5
A patent review of adenosine A2Breceptor antagonists (2016-present)5
Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections5
A patent review of CHK1 inhibitors (2019 – present)5
CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)5
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)5
Inhibitors of the GTPase KRASG12Cin cancer: a patent review (2019-2021)5
A patent review of MLKL modulators (2023 – present)5
A patent review of IDO1 inhibitors for cancer (2023 – present): an update5
Natural products as a source of new anticancer chemotypes5
Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)5
PIM kinase inhibitors: an updated patent review (2016-present)5
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)5
BET inhibitors: an updated patent review (2018–2021)5
Tricyclic boronic acids as broad-spectrum serine and metallo-β-lactamase inhibitors with in vitro activity against Acinetobacter b5
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)5
Coactivator-associated arginine methyltransferase 1 (CARM1) inhibitors: a patenting perspective (2018-present)5
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US202401326155
Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019–2024)5
Update on JNK inhibitor patents: 2015 to present5
0.031404972076416